A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003
Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare best supportive care plus oxaliplatin/ folinic acid/
5-FU versus best supportive alone in patients with gemcitabine refractory pancreatic cancer.